Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:European_Union
2014 |
| gptkbp:ATCCode |
M09AX03
|
| gptkbp:brand |
gptkb:Translarna
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:PTC_Therapeutics
|
| gptkbp:form |
oral suspension
granules for oral suspension |
| gptkbp:genericName |
ataluren
|
| https://www.w3.org/2000/01/rdf-schema#label |
Translarna
|
| gptkbp:indication |
nonsense mutation Duchenne muscular dystrophy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:PTC_Therapeutics
|
| gptkbp:mechanismOfAction |
promotes ribosomal readthrough of nonsense mutations
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:regulates |
gptkb:European_Medicines_Agency
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain headache |
| gptkbp:targetAudience |
patients with nonsense mutation DMD aged 2 years and older
|
| gptkbp:usedFor |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:bfsParent |
gptkb:PTC_Therapeutics
|
| gptkbp:bfsLayer |
7
|